{"url_path":"/sec/ndra/8-k/2026-07-09/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-076526-index.html","accession_number":"0001213900-26-076526","cik":"0001681682","ticker":"NDRA","issuer_name":"ENDRA Life Sciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-076526-index.html","primary_entity_key":"0001681682","primary_entity_name":"ENDRA Life Sciences Inc."},"word_count":364,"has_tables":true,"body_markdown":"**Item\n8.01. Other Events.**\n\n \n\nAs\npreviously disclosed, on April 20, 2026, The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Staff (the\n“Staff”) issued a letter to ENDRA Life Sciences Inc. (the “Company”) indicating that the Company’s\nstockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 was below the $2,500,000\nrequired minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”).\nOn April 27, 2026, in accordance with the Staff’s letter, the Company requested a hearing before the Nasdaq Hearing Panel, and\na hearing was held on May 28, 2026.\n\n \n\nOn\nJuly 8, 2026, the Company received written notice (the “Notice”) from Nasdaq indicating that the Company has regained compliance\nwith the Minimum Stockholders’ Equity Requirement.\n\n \n\nPursuant\nto Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a period of one year from July\n1, 2026.** **If, within the one-year monitoring period, the Staff finds the Company again out of compliance with any of Nasdaq’s\nListing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with\nrespect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect\nto that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, pursuant\nto the Notice, the Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with\nthe initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. Pursuant to the Notice, the Company will have\nthe opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company’s securities may\nbe at that time delisted from Nasdaq.\n\n \n\n1\n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**ENDRA\nLIFE SCIENCES INC.**\n\n \n \n \n\nDate:\nJuly 9, 2026\nBy:\n/s/\nAlexander Tokman\n\n \nName:\n\nAlexander\nTokman\n\n \nTitle:\nChief\nExecutive Officer\n\n \n\n2"}